This is the authors' abstract. We don't add key points for this paper.
These data suggest that perampanel is an orally active, noncompetitive, selective AMPA receptor antagonist with potential as a broad spectrum antiepileptic agent.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hanada et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: